Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of War, through the Defense Health Agency, is soliciting quotes from pharmaceutical manufacturers for inclusion in the Uniform Formulary under a Blanket Purchase Agreement and Additional Discount Program to support the Military Health System as mandated by 10 U.S.C. §1074g and 32 CFR §199.21. The solicitation, identified as HT9402-26-Q-9302, seeks pricing and clinical data for newly approved drugs including Lifyorli (a glucocorticoid receptor antagonist for oncology), Quiofic (a water-soluble vitamin), Widaplik (an antihypertensive), and Saphnelo (an immunosuppressive), with evaluations based on relative clinical effectiveness measured by metrics like Minimum Clinically Important Difference and Quality-Adjusted Life Years, and relative cost effectiveness using benchmarks such as Federal Supply Schedule pricing, Federal Ceiling Price, and TRICARE Retail Refund calculations. Manufacturers must submit complete NDC-11 pricing at four decimal places, package sizes, and clinical advantage documentation by the deadline of May 28, 2026, through electronic means to the designated point of contact, following templates for the UF BPA and UF ADP appendices. A pre-submission teleconference is scheduled for May 13, 2026, to clarify requirements. The Defense Health Agency in San Antonio, Texas, will administer the process, with award decisions made by the Pharmacy and Therapeutics Committee and subsequent approval by the DHA Director, leading to the establishment of agreements that govern formulary tier placement—Basic Core Formulary, Extended Core Formulary, or non-formulary—with pricing tied to quarterly retail pharmacy utilization and refund reconciliations via the TRICARE Retail Refund Website. No formal contract clauses, packaging standards beyond NDC alignment, inspection protocols, or socioeconomic set-asides are specified, and the evaluation is based on a trade-off approach rather than lowest price technically acceptable. Funding flows through program-specific mechanisms like the Industrial Funding Fee and Wholesale Acquisition Cost, without formal appropriation codes disclosed. All submissions must comply with submission formats, deadlines, and clinical data requirements, but no physical delivery, FOB terms, or quality inspection criteria are identified, as performance is transactional and tied to pharmacy benefit administration across the TRICARE network including mail-order, military treatment facilities, and retail providers.